ARKAY is a pharmaceutical company. It develops RK-01, an orally-active pancreatic beta-cell-centric combination product that provides sustained glycemic control for patients with Type 2 diabetes. The treatment is custom-designed and formulated to prevent pancreatic beta cell failure and decrease insulin resistance.